Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 11/20 | 0.62 |
| ▸ | KIT known ✓ | P10721 | 7/20 | 0.62 |
| ▸ | PDGFRA known ✓ | P16234 | 7/20 | 0.62 |
| ▸ | CSF1R known ✓ | P07333 | 4/20 | 0.62 |
| ▸ | FLT1 known ✓ | P17948 | 3/20 | 0.62 |
| ▸ | FLT4 known ✓ | P35916 | 3/20 | 0.62 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.62 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.62 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.62 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.62 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.62 |
| ▸ | MET known ✓ | P08581 | 1/20 | 0.62 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.62 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.62 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.62 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.62 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 0.62 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.62 |
| ▸ | ALK known ✓ | Q9UM73 | 1/20 | 0.62 |
| ▸ | HDAC1 known ✓ | Q13547 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL159486 | 0.99 | BTK (0.77) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL724300 | 0.98 | BTK (0.79) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL4427732 | 0.96 | BTK (0.75) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL725543 | 0.91 | BTK (0.67) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL15973689 | 0.88 | BTK (0.62) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL12575010 | 0.87 | BTK (1.00) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL17135511 | 0.85 | BTK (0.58) | BTKKDRKITPDGFRACSF1R | |
| Hydrochloric Acid SCHEMBL6125704 | 0.85 | BTK (0.56) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL28843997 | 0.84 | BTK (0.73) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL29884143 | 0.84 | BTK (0.73) | BTKKDRKITPDGFRACSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150231265-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | GUPTA MANISH K (US) | 2015-08-20 | — | — | US | disclosed |
| EP-2566331-B1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | GLAXO WELLCOME MFG PTE LTD (SG) | 2014-09-03 | — | — | EP | disclosed |
| EP-2566331-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | Glaxo Wellcome Manufacturing Pte Ltd (SG) | 2013-03-13 | — | — | EP | disclosed |
| US-20130023550-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | GLAXO WELLCOME MANUFACTURING PTE, LTD (SG) | 2013-01-24 | — | — | US | disclosed |
| US-20130012531-A1 | TREATMENT METHOD | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2013-01-10 | — | — | US | disclosed |
| EP-2521550-A1 | TREATMENT METHOD | Glaxo Wellcome Manufacturing Pte Ltd (SG) | 2012-11-14 | — | — | EP | disclosed |
| US-20120232102-A1 | Methods Of Administration And Treatment | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-09-13 | — | — | US | disclosed |
| EP-2329821-B1 | Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema | GLAXOSMITHKLINE LLC (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012103060-A1 | METHOD OF ADMINISTRATION AND TREATMENT | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-08-02 | — | — | WO | disclosed |
| US-20120165354-A1 | TREATMENT METHOD | GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) | 2012-06-28 | — | — | US | disclosed |
| US-20070208023-A1 | Cancer Treatment Method | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-06 | — | — | US | disclosed |
| WO-2007064753-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064752-A2 | TREATMENT OF OCULAR NEOVASCULAR DISORDERS SUCH AS MACULAR DEGENERATION, ANGIOD STREAKS, UVEITIS AND MACULAR EDEMA | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1755394-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20060252943-A1 | Chemical process | SMITHKLINE BEECHAM CORPORATION | 2006-11-09 | — | — | US | disclosed |
| EP-1515955-A4 | CHEMICAL PROCESS | SMITHKLINE BEECHAM CORP (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2006020564-A1 | PYRIMIDIN DERIVATIVES FOR THE TREATMENT OF MULTIPLE MYELOMA | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005105094-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-10 | — | — | WO | disclosed |
| EP-1515955-A2 | CHEMICAL PROCESS | SmithKline Beecham Corporation (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003106416-A2 | CHEMICAL PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208023-A1 | Cancer Treatment Method | TP53, TYMP, TOP2A | KDR 1918/4885KIT 295/4885PDGFRA 1333/4885 |
| US-20120232102-A1 | Methods Of Administration And Treatment | AGER, VEGFA, FLT4 | KDR 5/4885KIT 696/4885PDGFRA 61/4885 |
| US-20130023550-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | PIK3CA, PYGL, G6PC1 | KDR 25/4885KIT 419/4885PDGFRA 191/4885 |
| US-20150231265-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | PIK3CA, G6PC1, PIK3C2B | KDR 65/4885KIT 385/4885PDGFRA 333/4885 |
| US-20130012531-A1 | TREATMENT METHOD | FLT4, VEGFA, FLT1 | KDR 4/4885KIT 94/4885PDGFRA 30/4885 |
| US-20060252943-A1 | Chemical process | KDR, FLT4, FLT1 | KDR 1/4885KIT 57/4885PDGFRA 7/4885 |
| US-20120165354-A1 | TREATMENT METHOD | AGER, VEGFA, PDE6D | KDR 21/4885KIT 855/4885PDGFRA 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.